Clinical Trial: NCT07461831
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Beijing Tongren Hospital |
| Information Provided By: | Beijing Tongren Hospital |
| Last Update Posted: | 2026-09-30 |
Study Overview
Brief Summary
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: CD19/CD22 bispecific CAR-T cells
Other Study ID Numbers
- TRhos-CART-02
- 2025ZD0544300
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Beijing Tongren Hospital |
| Information Provided By: | Beijing Tongren Hospital |
| Last Update Posted: | 2026-09-30 |
Study Overview
Brief Summary
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: CD19/CD22 bispecific CAR-T cells
Other Study ID Numbers
- TRhos-CART-02
- 2025ZD0544300